Introduction: A Path to Cutting-Edge Treatment
For patients with serious or difficult-to-treat conditions — particularly cancer, rare diseases, and chronic illnesses where standard treatments have failed or are inadequate — clinical trials (临床研究 / 临床试验) represent a genuine opportunity to access the most advanced treatments in the world, often before they are commercially available and frequently at significantly reduced or zero cost.
Yet clinical trials remain poorly understood by most patients and families. Many people assume they are a “last resort” or that participation means being a “guinea pig.” In reality, clinical trials are the engine of medical progress — every treatment that exists today, from aspirin to immunotherapy, was once tested in a clinical trial. Understanding what they are, how they work, and how to access them is an essential part of navigating serious illness.
What Is a Clinical Trial?
A clinical trial is a carefully designed scientific study that tests a new medical intervention — a drug, device, procedure, or diagnostic tool — in human volunteers to determine whether it is safe and effective. Clinical trials are conducted according to strict protocols approved by ethics committees (Institutional Review Boards, IRBs) and regulated by national health authorities (in China: the National Medical Products Administration, NMPA 国家药品监督管理局).
Clinical trials are the only scientifically valid way to determine whether a new treatment works better than existing options. Without them, medicine cannot advance.
The Four Phases of Clinical Trials
Clinical trials are conducted in sequential phases, each answering different questions:
| Phase | Primary Question | Participants | Duration |
|---|---|---|---|
| Phase I | Is it safe? What is the right dose? | 20–100 (usually healthy volunteers or patients who have exhausted other options) | Months |
| Phase II | Does it work? What are the side effects? | 100–300 patients with the target condition | 1–2 years |
| Phase III | Is it better than current standard treatment? | 300–3,000+ patients; randomized controlled trial | 2–4 years |
| Phase IV | Long-term safety and effectiveness in real-world use? | Thousands of patients post-approval | Ongoing |
Most patients seeking to join a clinical trial for a serious condition will be looking at Phase II or Phase III trials, which test treatments that have already demonstrated some evidence of safety and efficacy.
Types of Clinical Trials
- Treatment trials: Test new drugs, drug combinations, surgical procedures, or radiation therapies; the most common type sought by patients
- Prevention trials: Test interventions to prevent disease in healthy or at-risk individuals (e.g., vaccines, lifestyle interventions)
- Diagnostic trials: Test new methods for detecting or diagnosing disease (e.g., new imaging techniques, biomarkers)
- Screening trials: Test methods for detecting disease in populations before symptoms appear
- Quality of life / supportive care trials: Test interventions to improve comfort and quality of life for patients with serious illness
- Expanded access / compassionate use: Allows patients with serious conditions to access investigational treatments outside of a formal trial when no alternatives exist; requires NMPA approval in China
Key Concepts Every Patient Should Understand
Randomization
In most Phase III trials, participants are randomly assigned (随机分组) to receive either the experimental treatment or the control (standard treatment or placebo). Randomization ensures that the two groups are comparable and that any difference in outcomes is due to the treatment, not other factors. Patients cannot choose which group they are assigned to.
Blinding
- Single-blind: The patient does not know which treatment they are receiving
- Double-blind: Neither the patient nor the treating physician knows which treatment is being given; the gold standard for reducing bias
- Open-label: Both patient and physician know which treatment is being given; common in oncology trials where blinding is impractical
Placebo
A placebo is an inactive substance (sugar pill, saline injection) that looks identical to the experimental treatment. In most cancer and serious disease trials, patients in the control group receive the current standard of care — not a placebo. Pure placebo-controlled trials are only ethical when no effective standard treatment exists.
Informed Consent (知情同意)
Before joining any clinical trial, patients must sign an informed consent document that explains in plain language: the purpose of the trial, what participation involves, potential risks and benefits, alternatives to participation, and the right to withdraw at any time without penalty. Informed consent is a legal and ethical requirement — no patient can be enrolled without it.
Eligibility Criteria
Every trial has specific inclusion and exclusion criteria that determine who can participate. These may include: specific diagnosis and disease stage, prior treatment history, age range, organ function requirements (kidney, liver, heart), performance status, and genetic/molecular tumor characteristics. Meeting these criteria is essential — they exist to protect patient safety and ensure the trial produces valid results.
Potential Benefits of Joining a Clinical Trial
- Access to cutting-edge treatments: Investigational drugs may be years away from commercial approval; trials provide early access to potentially superior therapies
- Cost reduction or elimination: The investigational drug is typically provided free of charge by the pharmaceutical sponsor; many associated tests and visits are also covered
- Enhanced monitoring: Trial participants receive more frequent and thorough medical monitoring than standard care patients
- Contributing to medical progress: Participation helps future patients benefit from better treatments
- Access to expert centers: Trials are conducted at leading academic medical centers with specialized expertise
Potential Risks and Limitations
- Unknown side effects: Investigational treatments may have side effects not yet fully characterized
- No guarantee of benefit: The experimental treatment may not be more effective than standard care; some trials show no benefit or even harm
- Randomization: You may be assigned to the control group and receive standard treatment rather than the experimental drug
- Time and travel burden: Trials often require more frequent hospital visits than standard care; may require travel to the trial center
- Strict protocol requirements: Participants must adhere to the trial protocol; missing visits or taking prohibited medications may result in withdrawal
- Withdrawal from trial: If the trial is stopped early or you are withdrawn, you may lose access to the investigational treatment
Cost Comparison: Clinical Trial vs. Standard Treatment
One of the most significant practical advantages of clinical trial participation is cost reduction. Here is a realistic comparison:
| Cost Component | Standard Treatment (Self-Pay) | Clinical Trial Participation |
|---|---|---|
| Investigational drug cost | Full price (e.g., immunotherapy: ¥20,000–50,000 RMB/month) | Free (provided by sponsor) |
| Trial-related tests (labs, imaging, biopsies) | Patient pays | Free (covered by sponsor) |
| Standard-of-care treatments | Patient pays | Patient pays (or insurance covers) |
| Hospitalization for trial procedures | Patient pays | Often covered by sponsor |
| Travel and accommodation | Patient pays | Patient pays (some trials provide stipends) |
| Physician consultation fees | Patient pays | Often covered by sponsor |
Example: A patient with advanced hepatocellular carcinoma (liver cancer) receiving atezolizumab + bevacizumab (standard first-line immunotherapy) would pay approximately ¥30,000–50,000 RMB per month out of pocket if not covered by insurance. Participation in a Phase III trial of a next-generation immunotherapy combination could provide the experimental drug free of charge, with all trial-related tests covered — potentially saving ¥300,000–600,000 RMB per year.
Important caveat: Not all costs are covered. Patients still pay for standard-of-care treatments, non-trial-related hospitalizations, and personal expenses. Always clarify exactly what is and is not covered before enrolling.
How to Find and Join a Clinical Trial in China
Step 1: Confirm Your Diagnosis and Molecular Profile
Most oncology trials require specific molecular or genetic tumor characteristics (e.g., EGFR mutation, PD-L1 expression, HER2 amplification, MSI-H status). Comprehensive molecular profiling (next-generation sequencing, NGS) of your tumor is often a prerequisite for trial eligibility. Ensure you have complete pathology and molecular reports before searching for trials.
Step 2: Search Clinical Trial Registries
- Chinese Clinical Trial Registry (ChiCTR): www.chictr.org.cn — the official Chinese registry; all trials conducted in China must be registered here
- ClinicalTrials.gov: www.clinicaltrials.gov — the US NIH registry; lists many international trials including those with Chinese sites
- NMPA Drug Clinical Trial Information Platform: www.chinadrugtrials.org.cn — NMPA-registered trials
- Search by: disease type, disease stage, prior treatment history, location (Shanghai), and phase
Step 3: Consult a Specialist at a Trial Center
Most clinical trials are conducted at major academic medical centers. In Shanghai, leading trial centers include Zhongshan Hospital, Renji Hospital, Ruijin Hospital, Shanghai Cancer Center, and Huashan Hospital. Request a consultation with the relevant specialist department to discuss trial eligibility.
Step 4: Pre-Screening and Eligibility Assessment
The trial team will review your medical records, pathology reports, and imaging to determine if you meet the eligibility criteria. Additional tests (blood tests, biopsies, imaging) may be required for pre-screening. This process typically takes 1–4 weeks.
Step 5: Informed Consent and Enrollment
If eligible, you will be invited to sign the informed consent document and formally enroll in the trial. Take time to read the consent document carefully and ask all your questions before signing.
Step 6: Trial Participation
Follow the trial protocol: attend all scheduled visits, take medications as directed, report side effects promptly, and avoid prohibited medications or activities. The trial team will monitor you closely throughout.
Questions to Ask Before Joining a Trial
- What phase is this trial, and what is already known about this treatment's safety and efficacy?
- What are the chances I will receive the experimental treatment vs. the control?
- What are the most common and most serious side effects of the experimental treatment?
- What happens if I experience serious side effects — will I receive treatment, and who pays?
- What costs are covered by the sponsor, and what will I need to pay myself?
- Can I continue my current medications while on the trial?
- What happens if the trial is stopped early or I need to withdraw?
- Will I have access to the experimental treatment after the trial ends if it works for me?
Where to Seek Expert Guidance in Shanghai
Zhongshan Hospital (中山医院), Fudan University
One of China's leading academic medical centers with an extensive clinical trial portfolio across oncology, hepatology, cardiology, and other specialties:
- Dr. Fan Jia (樊嘉) — Academician & President of Zhongshan Hospital; China's foremost liver cancer expert; leads multiple national and international clinical trials in hepatocellular carcinoma
- Dr. Shi Guoming (史国明) — Hepatobiliary Surgery & Liver Cancer specialist at Zhongshan Hospital; involved in liver cancer surgical and systemic therapy trials
How CMCS Can Help
Navigating the clinical trial landscape — identifying eligible trials, preparing documentation, coordinating pre-screening, and managing the logistics of trial participation — is complex and time-consuming, particularly for international patients. CMCS provides dedicated support throughout this process:
- Identification of relevant clinical trials at Shanghai's leading academic medical centers based on your diagnosis, stage, and molecular profile
- Pre-consultation review of pathology, molecular profiling, and imaging reports to assess trial eligibility
- Priority appointments with principal investigators and trial coordinators at Zhongshan, Renji, Ruijin, and other leading centers
- Medical interpretation during all consultations, informed consent discussions, and trial visits
- Coordination of pre-screening tests and documentation preparation
- Ongoing support throughout trial participation including side effect management coordination and follow-up
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 則留言